TY - JOUR
T1 - A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1
AU - Kelleher, Anthony D.
AU - Puls, Rebekah L.
AU - Bebbington, Mark
AU - Boyle, David
AU - Ffrench, Rosemary
AU - Kent, Stephen J.
AU - Kippax, Sue
AU - Purcell, Damian F.J.
AU - Thomson, Scott
AU - Wand, Handan
AU - Cooper, David A.
AU - Emery, Sean
PY - 2006/1
Y1 - 2006/1
N2 - An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 × 107 pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.
AB - An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 × 107 pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.
UR - http://www.scopus.com/inward/record.url?scp=33646045350&partnerID=8YFLogxK
U2 - 10.1097/01.aids.0000199819.40079.e9
DO - 10.1097/01.aids.0000199819.40079.e9
M3 - Article
SN - 0269-9370
VL - 20
SP - 294
EP - 297
JO - AIDS
JF - AIDS
IS - 2
ER -